entertainment -WSS

entertainment

author：hotspot 2025-09-30 11:00:55 Page View：953

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biogen joins immunology wave with $1.15 billion acquisition of HI
Next article： Supreme Court strikes down use of affirmative action

focus

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Biogen joins immunology wave with $1.15 billion acquisition of HI

RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

The leaders of Italy and Poland say European Union should focus on stopping migration

Poland'sPrimeMinisterMateuszMorawiecki,right,andItaly'sPrimeMinisterGiorgiaMelonispeakduringanewscon

entertainment

explore

focus

The leaders of Italy and Poland say European Union should focus on stopping migration